Cohance Lifesciences Ltd vs Indoco Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 16, 2026

Key Highlights

The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 423.2 as of 15 May 15:30 . The P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 yearsThe P/E Ratio of Indoco Remedies Ltd changed from 28.6 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 yearsThe Market Cap of Indoco Remedies Ltd changed from ₹ 2658 crore on March 2021 to ₹ 2152 crore on March 2025 . This represents a CAGR of -4.14% over 5 years The revenue of Cohance Lifesciences Ltd for the Mar '26 is ₹ 617.28 crore as compare to the Dec '25 revenue of ₹ 550.71 crore. This represent the growth of 12.09% The revenue of Indoco Remedies Ltd for the Mar '26 is ₹ 479.31 crore as compare to the Dec '25 revenue of ₹ 446.34 crore. This represent the growth of 7.39% The ebitda of Cohance Lifesciences Ltd for the Mar '26 is ₹ 80.33 crore as compare to the Dec '25 ebitda of ₹ 96.65 crore. This represent the decline of -16.89% The ebitda of Indoco Remedies Ltd for the Mar '26 is ₹ 53.41 crore as compare to the Dec '25 ebitda of ₹ 26.34 crore. This represent the growth of 102.77% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 8.31 crore over 8 quarters. This represents a CAGR of -66.80% The net profit of Indoco Remedies Ltd changed from ₹ 1.82 crore to ₹ -23.68 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Indoco Remedies Ltd changed from 14.96 % on March 2021 to -21.11 % on March 2025 . This represents a CAGR of NaN% over 5 years .

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

About Indoco Remedies Ltd

Indoco Remedies Limited, incorporated on August 23, 1947 is a Mumbai-based pharmaceutical company focused on formulations, with some presence in contract manufacturing and research.
The Company headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries.
The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Indoco, a USD 212 million company has 11 manufacturing facilities, 7 of which are for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. Currently, Indoco has a presence in therapeutic segments including anti-infective, anti-cold preparation, opthalmic, antispasmodic, stomatology, anti-inflammatory and anti-fungal.

FAQs for the comparison of Cohance Lifesciences Ltd and Indoco Remedies Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Indoco Remedies Ltd?

Market cap of Cohance Lifesciences Ltd is 16,190 Cr while Market cap of Indoco Remedies Ltd is 2,077 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Indoco Remedies Ltd?

The stock performance of Cohance Lifesciences Ltd and Indoco Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Indoco Remedies Ltd?

As of May 16, 2026, the Cohance Lifesciences Ltd stock price is INR ₹423.2. On the other hand, Indoco Remedies Ltd stock price is INR ₹225.05.

How do dividend payouts of Cohance Lifesciences Ltd and Indoco Remedies Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Indoco Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.